Electroconvulsive therapy (ECT) is the safe application of electricity to the scalp of a patient, using brief-pulse stimulation techniques under general anesthesia and muscle paralysis, inducing a series of generalized epileptic seizures. Principal indications for ECT are major depression (unipolar or bipolar) with a lack of response to medications, intolerance to medications due to side effects or coexisting conditions, the need for a rapid response because of other conditions such as catatonia, psychosis, suicidality, or clinically significant dehydration or malnutrition, mania, and schizophreniform disorder or schizoaffective disorder, and, medical disorders such as Parkinson's disease, neuroleptic malignant syndrome, and chronic pain. Anesthesia management of special patient populations undergoing ECT has been described in textbooks and guidelines, but some descriptions may be antiquated. Therefore, this review describes recent knowledge on anesthesia management of patients who require ECT, such as those with neurologic disorders, cardiovascular disorders, pregnancy, and other concurrent medical illness. Based on the findings of a recent paper, ECT may be safer than is widely reported. According to the American Psychiatric Association, ECT has no absolute contraindications; however, some conditions pose a relatively high risk, and there are many other kinds of complications associated with ECT that can lead to death. Understanding such complications and their management strategies can avoid unnecessary discontinuation of treatment due to manageable complications of ECT and, furthermore, ECT clinicians must also consider the risk-benefit ratio when treating high-risk patients. (J Nippon Med Sch 2019; 86: 70 80) 
Introduction
Electroconvulsive therapy (ECT) is the safe induction of a series of generalized epileptic seizures in a patient for therapeutic purposes, using brief-pulse stimulation techniques under general anesthesia and muscle paralysis 1 7 .
Since the earliest publications on the subject, the excellent therapeutic effectiveness of this method in the treatment of depression and other psychiatric disorders has been described in a variety of reviews and meta-analyses 5 , and medical disorders such as Parkinson's disease 8, 9 , neuroleptic malignant syndrome 8 , and chronic pain 10, 11 can also be indications for ECT.
Although anesthesia management of special patient populations undergoing ECT has been described in textbooks and guidelines 12 15 , some descriptions may be antiquated and, therefore, in this review I describe the recent knowledge on anesthesia management of such populations undergoing ECT by reviewing papers published after 2007 in English and Japanese that were retrieved through a bibliographic search of PubMed.
Neurologic Disorders Neuroleptic Malignant Syndrome (NMS)
NMS is a relatively rare, but potentially fatal complication of the use of neuroleptic or antipsychotic drugs 16 .
phokinase. Supportive therapy and pharmacological treatments for NMS, such as benzodiazepines, dopaminergic agents, and dantrolene are usually chosen, but ECT can also be effective 17, 18 . The use of succinylcholine may have potentially deteriorative effects on the cardiovascular system and plasma potassium levels and cause adverse effects in patients with a known history of susceptibility to malignant hyperthermia. Thus, in patients with a history of NMS, the recommended alternative to the customary administration of succinylcholine is a nondepolarizing relaxant such as rocuronium 18, 19 . The concomitant use of sugammadex, a reversal agent for rocuronium, is another alternative that may solve the problem of long-lasting effects caused by the other nondepolarizing relaxants that are substituted for succinylcholine in ECT for NMS without the adverse effects of the acetylcholinesterase inhibitors 18, 19 .
Malignant Catatonia, Catatonic Schizophrenia
Catatonic schizophrenia is characterized by at least two of the following: catalepsy or stupor, excessive motor activity; extreme negativism or mutism; peculiarities of voluntary movement as evidenced by posturing, stereotypical movements, prominent mannerisms, or prominent grimacing; and echolalia or echopraxia (American Psychiatric Association, 1994) 20 . Malignant catatonia, a particularly severe form, is the acute onset of excitement, fever, increasing autonomic instability (tachycardia, hypertension, fluctuating blood glucose levels, and hyperthermia), and delirium, and may be fatal 21, 22 . ECT is widely used and shown to be effective and safe in patients with catatonic schizophrenia (American Psychiatric Association,
2001
) 20 . Although the standard protocol can be applied in patients with catatonic schizophrenia 20 , special anesthesia care is required in patients with malignant catatonia in accordance with symptoms of their condition (increasing autonomic instability) such as tachycardia and hypertension.
Presence of Cranial Metallic Objects
Gahr et al. 23 reviewed the safety of ECT in the presence of cranial metallic objects (cMO) such as medical devices or metallic foreign bodies (cerebral clipping systems, cerebral coils, deep brain stimulators, osteosynthesis materials or other metallic medical devices, and foreign bodies). The presence of cMO raises three theoretical concerns regarding the safety of ECT: (1) cMO may significantly alter the ECT-induced electrical field distribution in the brain regarding field strength and focality, (2) vascular complications at the location of the cMO due to the ECT-induced hyperdynamic state may occur, and (3) a prolonged seizure or status epilepticus may develop during ECT as a consequence of device-induced symptomatic epilepsy. However, Gahr et al. 23 found that no ECTrelated complications related to the proposed theoretical concerns were reported, and concluded as follows: the absence of cMO-related complications during ECT in the reported cases implies that cMO might not represent an absolute contraindication for the performance of ECT.
However, the indication for ECT should be carefully considered in patients with cMO. Further research is considered necessary for the adequate assessment of safety.
Dopa-Responsive Dystonia (Segawa Syndrome)
Segawa syndrome is an autosomal dominant form of guanosine triphosphate cyclohydrolase deficiency that results in decreased dopamine and serotonin levels and typically presents as a dopa-responsive dystonia, with marked diurnal fluctuation, and an onset in childhood or early adulthood 9 . Publications to guide the clinician in the treatment of psychiatric conditions in patients with this syndrome are lacking 9 . Sienaert et al. 9 reported a patient with dopa-responsive dystonia who presented with a delusional depression and anxiety. They concluded that ECT can be administered safely and effectively in a patient with dopa-responsive dystonia 9 , and in any case, the possible benefits of ECT should be weighed against its possible risks.
Lycanthropy and Cotard Syndrome
Lycanthropy comes from the Greek lyk" nthropos, l! kos (wolf) + " nthr# pos (human), and describes the mythical condition of lycanthropy, a supernatural affliction in which people are said to physically transform into wolves 24 . In the psychiatric literature, lycanthropy is understood as an unusual belief or delusion that one has been transformed into an animal or that his/her behaviors or feelings are suggestive of such a belief, and besides being metamorphosed into a wolf, patients with this phenomenon have reported delusional transformation into a leopard, lion, elephant, crocodile, shark, buffalo, eagle, serpent, frog, bee, dog, gerbil, rabbit, horse, tiger, cat, bird, and other unspecified animal species 24 .
The phenomenon of lycanthropy has been reported in patients with schizophrenia, psychotic depression, bipolar disorders, use of cannabis and alcohol, personality disorders, and also in organic conditions 24 .
Cotard syndrome is a rare condition characterized by nihilistic delusions concerning body or life that can be found in several neuropsychiatric conditions. It is typically associated with depressive symptoms 25 . Grover et al. 24 effectively treated a patient presenting with lycan-thropy and Cotard syndrome with the use of bilateral modified ECT.
Cardiovascular disorders

Recent Myocardial Infarction (MI) and/or Reduced
Cardiac Output
There are limited reports on the use of ECT in patients with recent MI and in those with reduced cardiac output 26 . Use of ECT is associated with an increase in cardiac output, rise in blood pressure, and increase in heart rate lasting for a few minutes 1 3,6,7,26 . Accordingly, a thorough cardiac evaluation is considered to be mandatory prior to the use of ECT 7, 26 . Generally, the guidelines given by the American College of Cardiology/American Heart Association for non-cardiac procedures requiring general anesthesia are also followed for ECT 27, 28 , and these guide- Mueller et al. 32 
Idiopathic Pulmonary Arterial Hypertension (IPAH)
IPAH is a progressive and fatal cardiovascular disease if left untreated 22 . In patients with IPAH with psychiatric illness or other complications, careful attention is required when administering medical therapies that may affect their hemodynamics 22 . Patients suffering from IPAH who undergo anesthesia and surgery experience high rates of mortality and morbidity, and pulmonary hypertensive crisis (PHC) is the most serious complication that can be induced by the sympathetic stimulation of ECT 22 .
Hobo et al. 22 reported malignant catatonia in a patient with IPAH who eventually required ECT that could have affected the patient's hemodynamics. To avoid PHC, they administered oxygen using a laryngeal mask and administered remifentanil for anesthesia (chosen because it is a short-acting opioid with strong antinociceptive features and was expected to stabilize blood pressure), and they performed endotracheal intubation. Furthermore, standby nitric oxide inhalation was prepared in case of PHC secondary to dilation of the pulmonary arteries. During each ECT procedure, epoprostenol (PGI2) was continuously infused to prevent PHC.
Brugada Syndrome
Brugada syndrome is an inherited cardiac disorder in- Therefore, class IA anti-arrhythmic drugs should be avoided, and special caution should be exercised when neostigmine and α-agonists are used 33 . In patients with Brugada syndrome, vagotonic agents have been shown to accentuate ST-segment elevation and may trigger ventricular fibrillation 34 . Therefore, succinylcholine also should be avoided, and a non-depolarizing neuromuscular blocking agent, having characteristics of cardiovascular stability, can be used as a substitute in these patients 34 . Reversal of residual non-depolarizing neuromuscular block is necessary after the short ECT procedure;
however, the muscarinic effects of anticholinesterases such as neostigmine are also contraindicated 34 . Konishi et al. 34 reported that the combination of rocuronium and sugammadex was effectively and safely used to induce and antagonize neuromuscular block in a patient who underwent consecutive ECT sessions.
Prolonged QTc Intervals
The QT interval on the surface ECG represents the time of onset of ventricular depolarization to completion of repolarization 35 . This interval is usually reported as the QTc, which is the QT interval corrected for heart rate 35 .
The QTc value printed on ECG reports actually represents the mean QTc of all ECG leads because the values vary slightly from lead to lead 35 . 35 . One previous case study has suggested that high-pretreatment QTc dispersion can predict arrhythmias during ECT treatments 36 . Another study showed that ECT treatment itself was directly associated with a temporary prolongation of QTc dispersion immediately after the treatments 37 . However, with the exception of one case report 38 , there are no data addressing whether prolonged QTc intervals are associated with increased morbidity or mortality in ECT practice. Pullen et al. 35 investigated whether pretreatment prolongation of the QTc interval was associated with increased cardiacrelated events in the ECT treatment of psychiatric disorders. They found that the presence of baseline QTc prolongation was not independent of an increased risk of cardiac-related events during ECT, and they concluded that careful consideration should be given to patients with QTc prolongation on their ECG who are undergoing
ECT treatment, but this should not definitively exclude them from receiving ECT treatment.
Aortic Stenosis
Aortic stenosis is a risk factor for increased morbidity and mortality in patients undergoing procedures requir- .
Heart Failure and Decreased Left Ventricular Systolic Heart Function
Because little is known about the safety of ECT in patients with a history of heart failure and decreased LV systolic heart function, Rivera et al. 29 conducted a retrospective review of the medical records of 35 patients at their institution with such a history and assessed the safety of ECT in these patients. The median age was 77 years, the median LV ejection fraction was 30%, and the median number of sessions per patient was 10 (range, 1-44). Before undergoing ECT, none of the patients had symptoms of heart failure and all of the patients tolerated ECT well, none died or experienced decompensated heart failure, myocardial ischemia, or MI during or within 24 hours after an ECT session 29 . Prophylactic intravenous β-blockers were given to patients who had experienced marked hypertension or had a heart rate " 100 bpm during previous ECT sessions. Overall , and a preoperative medical evaluation that follows standard of care recommendations is advised 41 .
However, Rivera et al. 29 commented that ECT may not be safe in some patients with a history of heart failure and reduced systolic function and, finally, their findings cannot be generalized to patients with heart failure due to diastolic dysfunction, which is a pathophysiological condition different from that of heart failure due to systolic dysfunction.
Peripartum Cardiomyopathy
The incidence of psychotic illness in the puerperal period is low 42 . Peripartum cardiomyopathy is a rare lifethreatening cardiomyopathy of unknown cause that occurs in the peripartum period in previously healthy women 43 . Diagnosis is confined to a narrow period and requires echocardiographic evidence of LV systolic dysfunction 43 . Symptomatic patients should receive standard therapy for heart failure, managed by a multidisciplinary team 43 . If subsequent pregnancies occur, they should be managed in collaboration with a high-risk perinatal center 43 . Many of the antipsychotics are contraindicated dur-ing pregnancy, and ECT cannot be administered due to the added risks involved with regard to anesthesia 42 .
ECT use During Pregnancy
Pregnancy is a special situation in which pharmacotherapy during the first trimester risks major congenital malformations and pharmacotherapy during the last trimester risks drug toxicity or withdrawal effects. In addition, the use of some psychotropic drugs during pregnancy has been associated with fetal neurodevelopmental effects in some studies 44 . ECT has been suggested as an alternative to pharmacotherapy for pregnant women with major mental illness; the advantage is that the fetus is minimally exposed to transplacental transfer of chemical substances 44 . The subject of the safety of ECT during pregnancy has been reviewed in different manners by different teams of authors, resulting in differing results and conclusions. Therefore, Sinha et al. 44 recently compared these reviews with regard to search strategy, study selection criteria, total number of studies identified, total number of patients included, findings related to safety and adverse events, and interpretation of results. They found four systematic reviews that examined the safety of ECT in pregnancy 45 48 and concluded that the recommendations by Anderson et al. 46 and Pompili et al. 47 seemed to be the most balanced, and readers would do well to consider their conclusions.
Anderson et al. 46 concluded that ECT did seem to be effective in treating major mental illness during pregnancy, and the risks of adverse events were low. Accordingly, they suggested that ECT should be strongly considered in pregnant women with severe symptoms of mental illness, such as psychotic symptoms, catatonia, or strong suicidal urges.
Pompili et al. 47 found that severe psychiatric disorders are relatively common during pregnancy, with some studies reporting a morbidity rate of 15-29% among all pregnant women 49 . Pharmacological treatment of severe psychiatric disorders during pregnancy is complicated by the potential harmful effects to the fetus (e.g., teratogenicity, toxicity, and withdrawal syndromes). 47 Many authors have indicated the efficacy and safety of ECT during all trimesters of pregnancy. 47 Pompili et al. 47 Pulmonary function testing, particularly measures of obstruction (e.g., peak expiratory flow and forced expiratory volume in 1 sec.) are useful in the general management of COPD but are not specifically indicated before ECT, and a chest X-ray should be performed to screen for infections. Concomitant psychotropic medications should be minimized 51 . Schak et al. 51 empirically suggested that it seems reasonable to administer inhalers before ECT treatments prophylactically, but there is no evidence in the literature to support this practice. In addition, patients who are wheezing should receive inhaled β2-agonists and parenteral corticosteroids and, furthermore, unless the psychiatric indication for ECT is life-threatening, significant exacerbations of COPD should be treated first before administering ECT 51 .
When Succinylcholine is Contraindicated or Not Recommended
Although succinylcholine has been used during ECT for many years because of its rapid onset and short duration of action to prevent injury during seizures, 52 succinylcholine is contraindicated in patients with pseudocholinesterase deficiency 53 , muscular dystrophy 53 , Brugada syndrome 34 , and succinylcholine allergy 52 . González et al. 53 asserted that mivacurium is a suitable alternative to succinylcholine, based on its relatively short duration of action, because mivacurium is metabolized by plasma pseudocholinesterase; however, its use is not recommended in patients with pseudocholinesterase deficiency.
They also noted that although the use of rocuronium and sugammadex, which is an expensive drug whose high cost would limit its repeated use during ECT procedures, is attractive, it is probably the best option for ECT when succinylcholine is contraindicated 53 .
Systemic Lupus Erythematosus (SLE)/Neuropsychiatric SLE (NPSLE)
SLE is an autoimmune disorder that requires long-term management and can have a profound impact on patient quality of life 54 . Neuropsychiatric manifestations are fairly common, occurring in up to 75% of the patients with Tan et al. 54 described three patients who presented with psychosis during a lupus relapse, and were treated safely and successfully with ECT after their symptoms did not improve with medical treatment (antipsychotics and immunosuppressants). Hussain et al. 55 also described a patient with NPSLE presenting with catatonia that did not respond to benzodiazepines or immunosuppression but showed improvement with ECT. ECT may play an important role in the treatment of neuropsychiatric manifestations of SLE and should always be considered as a treatment option if the patient is resistant to medications 55 .
Patients Taking Steroid Medication
Patients who take chronic steroid medication are often prescribed extra "stress doses" before procedures involving general anesthesia 56 . The rationale for this practice is that their chronic steroid use has suppressed the ability of the endogenous hypothalamic-pituitary-adrenal steroid stress-reactivity system to handle the systemic stress of surgery 56 . Rasmussen et al. 56 described their experience treating 27 patients with ECT taking prednisone to investigate whether the stress of treatments was sufficient enough to warrant this practice in ECT, which has not been broached in the literature. They concluded that the use of extra "stress doses" of steroid medication is unnecessary in ECT practice and recommended that patients receive their usual morning dose of steroid before ECT treatments 56 .
Addison Disease
Addison disease, or primary adrenocortical insufficiency, is a rare disorder with a mean incidence of approximately 6 new cases per million per year 57, 58 . Major depression is a frequent occurrence in patients with Addison disease 57, 58 . Although glucocorticoid replacement may alleviate major depression in these patients, some have persistent major depression despite adequate replacement therapy 58, 59 . Major depression is associated with both hyper-and hypocortisolemia, with hypocortisolemia being more prevalent in patients with chronic major depression 58 . Whether the efficacy of antidepressants in patients with depression with Addison disease is similar to that in physically healthy patients with depression is unknown 58 . Nevertheless, Heijnen et al. 
Multiple Sclerosis (MS)
The prevalence of major depression among patients with MS is higher compared with that in the general population, and it occurs in approximately 50% of patients. Importantly, depressive symptoms such as a lack of energy, fatigue, and cognitive disorders can be misdiagnosed as MS-related symptoms 61 . Mattingly et al. 62 described three depressive patients with MS whose psychiatric symptoms were treated effectively with ECT, although one of the patients deteriorated neu- 
